Metraipolis › archive › dc_60d8cea00941

Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells — Europe PMC PMID:32633234

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/32633234
DOI
10.7554/elife.54854
License (as archived)
CC0-1.0
Archived
2026-11-08T06:03:47.027Z
SHA-256 of the archived text
dd5eb663b527fd182e440cb17fcb016be145a9e1c2d1e7e238488f20f7d5f425
Stable URL of this page
https://metraipolis.com/documento/dc_60d8cea00941

How to cite

Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells — Europe PMC PMID:32633234 — Europe PMC (en), https://europepmc.org/article/MED/32633234 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_60d8cea00941 (Metraipolis archive dc_60d8cea00941, sha256 dd5eb663b527fd182e440cb17fcb016be145a9e1c2d1e7e238488f20f7d5f425)
BibTeX
@misc{dc60d8cea00941,
  title = {Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells — Europe PMC PMID:32633234},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/32633234},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_60d8cea00941; sha256 dd5eb663b527fd182e440cb17fcb016be145a9e1c2d1e7e238488f20f7d5f425},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/32633234. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Failed T cell-based immunotherapies in the presence of genomic alterations in antigen presentations pathways may be overcome by NK cell-based immunotherapy. This approach may still be limited by the presence of immunosuppressive myeloid populations. Here, we demonstrate that NK cells (haNKs) engineered to express a PD-L1 chimeric antigen receptor (CAR) haNKs killed a panel of human and murine head and neck cancer cells at low effector-to-target ratios in a PD-L1-dependent fashion. Treatment of syngeneic tumors resulted in CD8 and PD-L1-dependent tumor rejection or growth inhibition and a reduction in myeloid cells endogenously expressing high levels of PD-L1. Treatment of xenograft tumors resulted in PD-L1-dependent tumor growth inhibition. PD-L1 CAR haNKs reduced levels of macrophages and other myeloid cells endogenously expressing high PD-L1 in peripheral blood from patients with head and neck cancer. The clinical study of PD-L1 CAR haNKs is warranted.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: eLife, 2020 (prima pubblicazione 2020-07-07).
Identificativi: PMID 32633234 · PMCID PMC7340502 · DOI 10.7554/elife.54854.
Parole chiave degli autori: Human; Mouse; Inflammation; NK cells; Myeloid; PD-L1; immunology; xenograft; Syngeneic; Chimerica Antigen Receptor.
Pagina: https://europepmc.org/article/MED/32633234 — https://doi.org/10.7554/elife.54854. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-08T05:59:09.946Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.